Solid Biosciences Inc.

Robbins LLP Is Investigating the Officers and Directors of Solid Biosciences Inc. (SLDB) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Solid Biosciences Inc. (NasdaqGS: SLDB) breached their fiduciary duties to shareholders. On March 14, 2018, Solid Biosciences announced that it received notification from the U.S. Food and Drug Administration that the company’s Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy had been placed on clinical hold. Since the disappointing news was announced, Solid Biosciences’ stock has fallen over 67% to close at $8.50 per share on March 26, 2018—47% below the company’s January 26, 2018 initial public offering price of $16 per share.

Solid Biosciences Inc. (SLDB) Express Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies send us a message via the Shareholder Information form below.

Send us a message for more information.

Skip to content